Use of a super active luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia

In: BJOG: An International Journal of Obstetrics & Gynaecology · 1984 · vol. 91(9) , pp. 913–916 · doi:10.1111/j.1471-0528.1984.tb03708.x · PMID:6433966 · W1983938772
article OA: closed CC0 ⤵ 17 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by gemini-2.5-flash-lite, 2026-06-08

Intranasal administration of a super active LHRH agonist significantly reduced menorrhagia in four women, with blood loss returning to baseline after therapy cessation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A luteinizing hormone releasing hormone agonist, D-Ser(But)6des Gly10-LHRH ethylamide, was administered intranasally to four women with unexplained ovulatory menorrhagia. Dramatic reductions in excessive menstrual blood losses were induced without significant side-effects, although the pattern of loss returned to pretreatment levels within 2 months of ceasing therapy.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (9)

Cited by (16)

SciLite annotations

organisms 1
noordeloos 2009062

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
scilite
last seen: 2026-05-18T04:57:49.680383+00:00
License: CC0 · commercial use OK